Startsida4559 • TYO
add
Zeria Pharmaceutical Co Ltd
Föregående stängning
2 244,00 ¥
Dygnsintervall
2 247,00 ¥ - 2 274,00 ¥
Årsintervall
1 921,00 ¥ - 2 411,00 ¥
Börsvärde
119,89 md JPY
Genomsnittlig volym
63,62 tn
P/E-tal
11,85
Direktavkastning
1,99 %
Primär börs
TYO
Ekonominyheter
Ekonomi
Resultaträkning
Intäkter
Nettoinkomst
(JPY) | sep. 2024info | Förändring Y/Y |
---|---|---|
Intäkter | 20,97 md | 14,11 % |
Rörliga kostnader | 12,52 md | 14,20 % |
Nettoinkomst | 1,85 md | −25,47 % |
Nettovinstmarginal | 8,82 | −34,67 % |
Vinst per aktie | — | — |
EBITDA | 4,39 md | 8,29 % |
Giltig skattesats | 17,59 % | — |
Balansräkning
Totala tillgångar
Totala ansvarsskyldigheter
(JPY) | sep. 2024info | Förändring Y/Y |
---|---|---|
Kontanta och kortsiktiga investeringar | 24,36 md | 31,90 % |
Totala tillgångar | 158,34 md | 6,87 % |
Totala ansvarsskyldigheter | 69,77 md | −3,36 % |
Totala tillgångar | 88,57 md | — |
Utestående aktier | 44,08 mn | — |
P/B | 1,12 | — |
Avkastning på tillgångar | 4,06 % | — |
Avkastning på kapital | 4,89 % | — |
Kassaflöde
Förändring i nettokassa
(JPY) | sep. 2024info | Förändring Y/Y |
---|---|---|
Nettoinkomst | 1,85 md | −25,47 % |
Kontanter från verksamhet | — | — |
Kontanter från investering | — | — |
Kontanter från finansiering | — | — |
Förändring i nettokassa | — | — |
Fritt kassaflöde | — | — |
Om
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
Grundades
22 dec. 1955
Hemsida
Anställda
1 777